Building the Preparation Plan

Where "the preparation plan" sits in the standard

The Readiness Standard's Common Core runs Screen → Prepare → Clear-to-Treat. Module P5 is entirely about the middle step: what you actually build, document, and time once a patient has passed Phase 1 screening and before the treating clinician signs off at Phase 3. A preparation plan is not a wellness program, and it is not a substitute for the patient's own clinic protocol — it is a conservative, documented bridge between "screened" and "cleared," and every decision inside it is either yours to make as the treating clinician or the prescriber's to make on a timeline you control.

Three commitments run through this module: conservative, test-first terrain work with no reflexive chelation; deliberate attention to set, setting, and psychological readiness; and a caregiver who is prepared, not merely informed. None of it is presented as proof that preparation changes a treatment's outcome — that remains an open question this standard's registry is built to test, not a claim this module makes.

"Prepare, then treat" is already accepted practice

You do not have to sell this idea to colleagues — the leading clinical model already practices it. In a Stanford-affiliated observational study of 30 Special Operations veterans undergoing magnesium–ibogaine treatment for TBI-related disability, PTSD, depression, and anxiety, the protocol pre-loaded magnesium specifically to blunt ibogaine's cardiac risk before dosing (Cherian et al., 2024, Nature Medicine). Established That is a preparation step, built into a real protocol, aimed at a specific, named danger. Building a preparation plan means generalizing that same discipline — screen for the medicine's specific danger, then prepare conservatively for it — to whichever modality your patient is approaching.

What is not established is whether preparation of any kind changes the treatment's psychiatric or functional outcome. Hypothesis Say this to patients and caregivers as plainly as you would want it said to you: the preparation plan makes the treatment day measurably safer; it is not sold, and should not be described, as something that makes the medicine "work better."

Terrain optimization: the low-risk, generally-beneficial layer

"Terrain" work covers sleep, hydration, nutrition, reduced alcohol and stimulant intake, and management of inflammatory, metabolic, and vascular risk factors. Plausible Chronic neuroinflammation — activated microglia, elevated inflammatory cytokines, reduced BDNF signaling — is a recognized contributor to impaired neuroplasticity, and several of these medicines are thought to work partly through BDNF-TrkB-mTOR-driven synaptic remodeling. It is biologically reasonable that the inflammatory and metabolic terrain a patient brings to that process matters. It is a separate, unproven claim that optimizing terrain improves this population's actual treatment outcomes. Hypothesis Document terrain work as good general-health practice with a plausible mechanistic rationale — not as an efficacy intervention.

The chelation guardrail: test first, treat conservatively, never reflexively

This is the single most important safety rule in this module, and it cuts against the instinct many wellness-minded patients — and some clinicians — bring to "detox." Do not chelate, and do not run an aggressive detoxification protocol, without first testing for and confirming a genuine toxicant burden. Established Two findings should anchor your thinking:

• Blood-metal levels are a poor proxy for brain-metal levels. In rodent studies, reductions in blood lead measurably overestimated reductions in brain lead after chelation (Stangle et al., 2004, Environmental Health Perspectives) — a "clean" blood test after chelation does not confirm the brain burden actually came down.
• Chelating a patient who is not actually overloaded is not a neutral act. In controlled rodent studies, succimer chelation given to non-lead-exposed animals produced lasting adverse neurobehavioral effects (Smith & Strupp, 2013, Journal of Medical Toxicology) — direct evidence that chelation carries its own risk, independent of any benefit.

The rule this supports: test first, act on a confirmed burden only, treat conservatively, and never chelate a patient who has not been shown to be overloaded. There is a second, treatment-specific reason to be conservative: aggressive detoxification can shift the electrolytes — potassium, magnesium, calcium — that govern cardiac-rhythm safety. Established For a patient approaching a cardiotoxic drug like ibogaine, that makes chelation or aggressive detox close to a treatment day a genuine hazard, not a precaution — it must never be done near dosing without direct physician oversight, and ideally not at all unless a real burden has been confirmed well in advance.

Anchor the plan to the medicine's signature risk

Every modality carries one danger the preparation plan has to be built around. Ibogaine is the clearest worked example, and the one most preparation plans will need to get right. Ibogaine and its long-lived active metabolite noribogaine block the cardiac hERG potassium channel and prolong the QT interval — a mechanism capable of fatal ventricular arrhythmia at therapeutic doses, even in patients with no pre-existing heart disease, with risk persisting for days after dosing because noribogaine clears slowly (Schep et al., 2016, Drug and Alcohol Dependence). Established

Ibogaine is converted to noribogaine primarily by CYP2D6. In a controlled human pharmacokinetics study, pretreatment with the CYP2D6 inhibitor paroxetine (a commonly prescribed SSRI) roughly doubled total active-moiety exposure compared with placebo, leading the study authors to recommend genotyping patients ahead of treatment and at least halving the dose in confirmed poor metabolizers (Glue et al., 2015, Journal of Clinical Pharmacology). Established An SSRI on a patient's medication list is a genuine cardiac-risk multiplier for ibogaine, not an incidental detail — full medication reconciliation is a safety step, not a formality.

• Baseline 12-lead ECG with QTc, repeated close to the treatment date.
• Electrolyte correction — potassium, magnesium, calcium — confirmed normal, not just "in range," before dosing.
• Hepatic panel, since ibogaine metabolism and elimination depend on it.
• Full medication and supplement reconciliation for CYP2D6 inhibitors (several SSRIs), other QT-prolonging drugs, and serotonergic agents relevant to whichever medicine is being prepared for.
• Continuous cardiac monitoring during the ibogaine session, alongside magnesium loading to buffer cardiac risk, is standard in leading protocols — both are dosing-day, clinician-owned decisions, not preparation-plan items decided independently.

Medication adjustments are the prescriber's decision alone

Some patients need a supervised taper before treatment — most commonly a serotonergic medication before MDMA or ibogaine, given serotonin-syndrome and CYP2D6-interaction risk respectively. Whether to taper, which drug, how fast, and on what timeline relative to the treatment date belongs solely to the treating prescriber. Established A preparation plan can flag the need and the timeline pressure; it cannot make or execute that call, and it should never be attempted through an education module or a supplement protocol. Document the taper plan and its target completion date as an input to the Phase 3 handoff, not as something the preparation plan itself manages.

Set and setting: the psychological and environmental half of the plan

A preparation plan that only addresses labs and medications is half a plan. The psychological and environmental context of the dosing session — intention-setting, a trained support person present, a physically safe and monitored setting, and a planned integration process afterward — is standard practice across clinical psychedelic research and is treated as a baseline safety measure. Plausible Be precise with patients about what this is and is not: a prepared setting and a trained sitter are a well-established consensus safety practice for reducing acute psychological distress during and after dosing; a rigorously controlled trial proving that better "set and setting" changes long-term treatment outcomes does not currently exist, so it should not be oversold as an efficacy lever.

Preparing the caregiver, not just the patient

Informed consent in this standard explicitly includes confirmation that the patient and the caregiver have both completed honest education about benefits, risks, and unknowns. Established A caregiver who shows up informed but unprepared is a gap in the plan, not a detail. Build the caregiver's role into the same document used for the patient:

• Confirm the caregiver has completed the same honest-education content as the patient — same content, same rigor, no shortcuts.
• Define what the caregiver's role is and is not during and after the session — support, not supervision of medical risk.
• Give the caregiver a specific, written escalation path: which symptoms mean "call the clinical team now" (chest pain, irregular heartbeat, fainting, prolonged confusion, suicidal statements) versus which are expected and transient.
• Confirm the caregiver knows the crisis resource for the population you serve — for veterans, the Veterans Crisis Line (988, then press 1) — before, not after, the treatment day.

Sequencing: everything on the treating clinician's timeline

A preparation plan is a timeline, not a checklist completed all at once. Terrain optimization runs continuously in the weeks before treatment. Toxicant testing, if indicated, happens well before the treatment date — never as a last-minute addition. Any prescriber-directed medication taper is timed to that specific drug's pharmacology, set by the prescriber. Electrolyte correction and the baseline ECG/QTc are confirmed close to the treatment date, and nothing that could destabilize electrolytes — including chelation or aggressive detox — is scheduled anywhere near it. Every one of these threads converges at the Phase 3 Clear-to-Treat documentation packet, which the treating clinician reviews and signs. Established

The go/no-go decision is the treating clinician's alone. This standard documents readiness; it does not clear anyone. Established The framework flags — and the treating physician sets exact thresholds and makes the call on — significant or uncontrolled cardiovascular disease or arrhythmia, uncorrected electrolyte abnormalities, significant hepatic or renal impairment, active psychosis or unmanaged bipolar disorder, acute suicidality, pregnancy, and contraindicated concurrent medications that cannot be safely managed. Any one of these halts the preparation plan and routes the patient back to the clinician, not forward to dosing.

What this preparation plan is — and isn't